Health + Wellness
cervilenz inc. offers another tool for doctors and pregnant women
Five months after the commercial launch of its medical device, CerviLenz Inc. of Chagrin Falls is ramping up for a national marketing push in the third quarter.
The wand-like CerviLenz measures the vaginal cervical length of pregnant women showing signs of preterm labor. In August, Ob.Gyn. News reported that in a study involving 52 women, CerviLenz was "similar in efficacy" to another widely used test that, unlike a CerviLenz test, requires lab work.
"Immediate and quantifiable measures of cervical length using the CerviLenz probe may be less variable than the most common way of measuring — by digital exam — and speedier than waiting for fetal fibronectin [test] results," according to Ob.Gyn. News.
The device helps reduce the guesswork in treatment: The article notes that only 21-27 percent of women with symptoms of preterm labor will actually deliver prematurely. And, "In asymptomatic women, cervical length shorter than 25 mm has been linked to a sixfold increase in risk for preterm birth."
About 25 hospitals are currently evaluating the product. "The hospital purchasing process is really complicated," with multiple rounds of testing, says Melanie Sweeney, CerviLenz Inc.'s director of marketing. But the company should soon start receiving the feedback it will need for a major sales push.
CerviLenz Inc.'s backers include Cleveland-based JumpStart Inc., North Coast Angel Fund of Mayfield Heights and Chrysalis Ventures, which has a Cleveland office.
Source: CerviLenz Inc.
Writer: Frank W. Lewis
The wand-like CerviLenz measures the vaginal cervical length of pregnant women showing signs of preterm labor. In August, Ob.Gyn. News reported that in a study involving 52 women, CerviLenz was "similar in efficacy" to another widely used test that, unlike a CerviLenz test, requires lab work.
"Immediate and quantifiable measures of cervical length using the CerviLenz probe may be less variable than the most common way of measuring — by digital exam — and speedier than waiting for fetal fibronectin [test] results," according to Ob.Gyn. News.
The device helps reduce the guesswork in treatment: The article notes that only 21-27 percent of women with symptoms of preterm labor will actually deliver prematurely. And, "In asymptomatic women, cervical length shorter than 25 mm has been linked to a sixfold increase in risk for preterm birth."
About 25 hospitals are currently evaluating the product. "The hospital purchasing process is really complicated," with multiple rounds of testing, says Melanie Sweeney, CerviLenz Inc.'s director of marketing. But the company should soon start receiving the feedback it will need for a major sales push.
CerviLenz Inc.'s backers include Cleveland-based JumpStart Inc., North Coast Angel Fund of Mayfield Heights and Chrysalis Ventures, which has a Cleveland office.
Source: CerviLenz Inc.
Writer: Frank W. Lewis